BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 38087654)

  • 1. Alopecia areata: What's new in the diagnosis and treatment with JAK inhibitors?
    Dainichi T; Iwata M; Kaku Y
    J Dermatol; 2024 Feb; 51(2):196-209. PubMed ID: 38087654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Janus kinase inhibitors for alopecia areata.
    King BA; Craiglow BG
    J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
    Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
    J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Systematic review of newer agents for the management of alopecia areata in adults: Janus kinase inhibitors, biologics and phosphodiesterase-4 inhibitors.
    Gupta AK; Wang T; Polla Ravi S; Bamimore MA; Piguet V; Tosti A
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):666-679. PubMed ID: 36478475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
    Eisman S; Sinclair R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areata.
    Zhou C; Yang X; Yang B; Yan G; Dong X; Ding Y; Fan W; Li L; Yang D; Fang H; Ji C; Cheng H; Zhang S; Goh AH; Liu R; Gu X; Weng Z; Foley P; Sinclair R; Zhang J
    J Am Acad Dermatol; 2023 Nov; 89(5):911-919. PubMed ID: 37019385
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Janus kinase inhibitors for alopecia areata: A narrative review.
    Haughton RD; Herbert SM; Ji-Xu A; Downing L; Raychaudhuri SP; Maverakis E
    Indian J Dermatol Venereol Leprol; 2023; 89(6):799-806. PubMed ID: 37436019
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Janus Kinase Inhibitors in the Treatment of Alopecia Areata.
    Stefanis AJ
    Prague Med Rep; 2023; 124(1):5-15. PubMed ID: 36763827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
    Ismail FF; Sinclair R
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
    [No Abstract]   [Full Text] [Related]  

  • 11. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
    Ramot Y; Zlotogorski A
    Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
    Husein-ElAhmed H; Husein-ElAhmed S
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Janus kinase inhibitors for the treatment of alopecia areata].
    Kobal I; Ramot Y
    Hautarzt; 2022 May; 73(5):336-343. PubMed ID: 35482047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging drugs for alopecia areata: JAK inhibitors.
    Iorizzo M; Tosti A
    Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JAK Inhibitors for Treatment of Alopecia Areata.
    Wang EHC; Sallee BN; Tejeda CI; Christiano AM
    J Invest Dermatol; 2018 Sep; 138(9):1911-1916. PubMed ID: 30057345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis.
    Yan T; Wang T; Tang M; Liu N
    Front Pharmacol; 2024; 15():1372810. PubMed ID: 38659584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overview of alopecia areata for managed care and payer stakeholders in the United States.
    King B; Pezalla E; Fung S; Tran H; Bourret JA; Peeples-Lamirande K; Takiya L; Napatalung L
    J Manag Care Spec Pharm; 2023 Jul; 29(7):848-856. PubMed ID: 37219075
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Therapeutic Potential of Ritlecitinib for the Treatment of Alopecia Areata.
    Ramírez-Marín HA; Tosti A
    Drug Des Devel Ther; 2022; 16():363-374. PubMed ID: 35210753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Evolving Story of JAK Inhibitors for Treating Alopecia Areata: A Review of Current Progress and Future Directions.
    Donovan J
    Skin Therapy Lett; 2023 May; 28(3):1-7. PubMed ID: 37339501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.